Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-11-22FDA Approved: QUETIAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approves a supplemental application for Quetiapine by Accord Healthcare Inc., granting regulatory approval for a generic version of the …
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: Antipsychotic Effects of Oxytocin [NA]
A terminated clinical trial evaluating antipsychotic effects of oxytocin in schizophrenia with results posted in 2019.
-
FDA approval · 2019-11-12FDA Approved: RISPERIDONE — Supplemental Application (Ajanta Pharma USA Inc.)
The FDA approved Ajanta Pharma USA Inc.'s supplemental application for risperidone, authorizing a generic version of the antipsychotic.
-
CLINICAL_TRIALS trial_result · 2019-11-08Clinical Trial Update: A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder [Phase 4]
Phase 4 trial evaluating all-cause hospitalizations for Abilify MyCite users versus virtual matched controls in adults with schizophrenia, b…
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: A Study of Staccato Loxapine (ADASUVE®) for Inhalation [Phase 3]
Phase 3 study update for Staccato Loxapine (ADASUVE) inhalation addressing psychomotor agitation and schizophrenia (potentially bipolar diso…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: Reducing Cardiovascular Risk in Adults With Serious Mental Illness [NA]
Clinical trial update on reducing cardiovascular risk in adults with serious mental illness; study completed with results posted in 2019.
-
FDA approval · 2019-10-29FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for HALOPERIDOL DECANOATE submitted by Sagent Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2019-10-23Clinical Trial Update: Aerobic Exercise for Cognition in Schizophrenia [NA]
Completed clinical trial evaluating aerobic exercise for cognition in schizophrenia; results posted in 2019.
-
FDA approval · 2019-10-22FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for ZYPREXA Intramuscular (olanzapine) from Eli Lilly. The approval relates to a supplemental su…
-
FDA approval · 2019-10-22FDA Approved: ZYPREXA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for ZYPREXA (olanzapine) submitted by Eli Lilly and Company, resulting in updated labeling to re…
-
FDA approval · 2019-10-22FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC. This action supplements th…
-
FDA label_change · 2019-10-22FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for ZYPREXA ZYDIS (olanzapine) submitted by Eli Lilly and Company, resulting in labeling changes…
-
FDA approval · 2019-10-22FDA Approved: HALOPERIDOL DECANOATE — Original Application (BluePoint Laboratories)
The FDA approved BluePoint Laboratories' haloperidol decanoate long-acting injectable under an original application for the treatment of sch…
-
FDA approval · 2019-10-11FDA Approved: SECUADO — Original Application (Noven Therapeutics, LLC)
FDA approved SECUADO (asenapine) from Noven Therapeutics in an original NDA (212268) for treatment of schizophrenia and acute manic/mixed ep…
-
CLINICAL_TRIALS trial_result · 2019-10-03Clinical Trial Update: A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia [Phase 2, Phase 3]
A dose-finding study of OPC-34712 in schizophrenia completed (Phase 2/Phase 3).
-
CLINICAL_TRIALS trial_result · 2019-10-02Clinical Trial Update: Glucose and Lipid Metabolism on Antipsychotic Medication [NA]
Clinical trial completed studying glucose and lipid metabolism effects of antipsychotic medication in schizophrenia-related conditions; resu…
-
CLINICAL_TRIALS trial_result · 2019-09-25Clinical Trial Update: Oxytocin Add on Study for Stable Schizophrenic Patients [NA]
A terminated clinical trial investigating oxytocin as an add-on treatment for stable schizophrenia patients; results posted in 2019.
-
FDA approval · 2019-09-23FDA Approved: PALIPERIDONE — Original Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's generic paliperidone, authorizing a new generic antipsychotic for schizophrenia. This represen…
-
CLINICAL_TRIALS research · 2019-09-19Clinical Trial Update: Benefits of Physical Exercise in Schizophrenia [NA]
Clinical trial update exploring benefits of physical exercise in individuals with schizophrenia; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet [Phase 4]
Phase 4 trial comparing patient preference between conventional oral olanzapine tablets and olanzapine orodispersible tablets in schizophren…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women [Phase 4]
Phase 4 trial evaluating adjunctive selective estrogen receptor modulators for negative and cognitive symptoms in women with schizophrenia h…
-
CLINICAL_TRIALS trial_result · 2019-09-04Clinical Trial Update: Oxytocin as Adjunctive Treatment of Schizophrenia [Phase 2]
Phase 2 trial evaluating oxytocin as an adjunctive treatment for schizophrenia has completed with results posted.
-
FDA approval · 2019-09-04FDA Approved: LURASIDONE HYDROCHLORIDE — Original Application (Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approves a generic version of lurasidone hydrochloride under an original ANDA filed by Heritage Pharma Labs Inc. d/b/a Avet Pharmaceutic…
-
CLINICAL_TRIALS trial_result · 2019-09-03Clinical Trial Update: Anti-inflammatories and Adolescent Schizophrenia [Phase 4]
Phase 4 clinical trial update involving anti-inflammatory agents for adolescents with schizophrenia.
-
FDA approval · 2019-08-26FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for SEROQUEL XR (quetiapine) from AstraZeneca Pharmaceuticals LP.